GLP-1 Agonist Therapy Center

Analysis of the PIONEER 8 trial reveals dose-dependent reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens.

A new study compares GLP-1 receptor agonists with known cardiovascular benefits against each other, rather than against the traditional placebo. 

Danish study makes strong recommendations for diabetes pharmacotherapy beyond metformin. 

We were following up with a person with type 2 diabetes who was recently started on the new oral formulation of the GLP-1 receptor agonists semaglutide (Rybelsus®). This patient had a 12-year history of type 2 diabetes as well as several comorbidities that included hypertension, hyperlipidemia, obesity (BMI = 33 kg/m2), knee osteoarthritis, and hypothyroidism. The patient was previously resistant to initiating a GLP-1 receptor agonist due to his hesitancy toward self-injection. He agreed at his last primary care visit to start a trial of oral semaglutide to improve his glucose control and lose some weight....

The MAG1C interventional study was a single-center, 26-week, phase 2a, to look at how Exenatide might benefit patients with type 1 diabetes. 

Eliminating childhood obesity, one injection at a time.

Which GLP-1RA provides better benefits?

Results from a phase 3 trial investigating the use of liraglutide in children and adolescents. 

A better understanding of clinical characteristics can lead to more effective therapy being implemented earlier, and fewer complications. 

Adding Dulaglutide, Liraglutide or Semaglutide (GLP-1 agonists) to existing treatment for type 2 diabetes has major cardiovascular benefits.  Exenatide* and Lixisenatide were neutral for providing cardiovascular benefits.